drugset
drugset / Trial / NCT05023070

Investigation of the Pharmacokinetic Profile of CBD - Phase 1 ANANDA

NCT05023070 ↗

Phase 1 Completed 24 enrolled Icahn School of Medicine at Mount Sinai
Non-randomizedCrossoverOpen-labelOther

Summary

The goal of the current study is to evaluate the bioavailability of CBD in normal healthy Individuals. This is an open cross-over design study in healthy individuals to assess the safety and pharmacokinetic (PK) effects of cannabidiol.

Timeline

Start
2021-07-22
Primary completion
2023-02-16
Completion
2023-02-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 200 mg —
Subject Cannabidiol Other / unclassified 400 mg —

Indications

No indication recorded.